ArticleAnnals of neurosciences2026
To Study the Effect of Nilotinib, a Tyrosine Kinase Inhibitor, on Learning and Memory and Its Comparison with Nitric Oxide Synthase Inhibitor in an Animal Model of Alzheimer's Disease.
Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a gradual neurodegenerative disorder presenting with cognitive and non-cognitive impairment. Currently approved therapies alleviate symptoms but do not modify disease progression and may be associated with adverse effects. Objective: This study aimed to compare the effect of nilotinib (a tyrosine kinase inhibitor) and Methods: Thirty adult male Wistar rats were randomly assigned to five groups ( Results: Scopolamine increased transfer latency in the EPM and escape latency in the MWM and increased AChE and Aβ1-42 levels, but it decreased PARK-7. Both nilotinib and L-NAME significantly reduced transfer latency and escape latency compared to scopolamine (all Conclusion: Nilotinib and L-NAME improved cognitive function and modulated cholinergic, amyloid and autophagy-related markers in a rat model of AD. Nilotinib demonstrated superior efficacy to L-NAME and may represent a potential therapeutic strategy for AD. Further studies are warranted to evaluate long-term effects and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.